Last reviewed · How we verify
Viibryd (vilazodone)
At a glance
| Generic name | vilazodone |
|---|---|
| Sponsor | AbbVie |
| Target | 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 4, 5-hydroxytryptamine receptor 7 |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Major depressive disorder
Boxed warnings
- WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions (5.1)]. Vilazodone hydrochloride tablets are not approved for use in pediatric patients [see Use in Specific Populations (8.4)]. WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. • Antidepressants increase the risk of suicidal thoughts and behaviors in pediatric and young adult patients (5.1). • Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors (5.1). • Vilazodone hydrochloride tablets are not approved for use in pediatric patients (8.4).
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Insomnia
- Sedation
- Tremor
- Dry eye
- Vision blurred
- Hyperhidrosis
- Night sweats
- Ventricular extrasystoles
- Migraine
Key clinical trials
- Vilazodone for Separation Anxiety Disorder (Phase 4)
- Double-Blind Switch Study of Vilazodone in the Treatment of Major Depressive Disorder Following Partial Response to or Inability to Tolerate a Generic SSRI (Phase 2)
- Vilazodone for Corticosteroid-Induced Memory Impairment (Phase 2)
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Study With Vilazodone in Patients With Major Depressive Disorder (Phase 4)
- A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive Disorder (Phase 3)
- Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression (Phase 2)
- A Double-blind, Placebo-controlled, Fixed-dose Study of Vilazodone in Patients With Major Depressive Disorder (Phase 4)
- A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder (Phase 3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |